What is claimed is:

1. A pharmaceutical composition comprising:

about 10 mg pazopanib/mL of the composition;

from about 2.0 to about 13.0 % w/w of a modified cyclodextrin, said modified cyclodextrin being selected such that the modified cyclodextrin results in the pK_a of pazopanib with said modified cyclodextrin in water being lower than the pK_a of pazopanib alone in water;

a pH adjusting agent as needed to provide a pH of 3.5 to 5.7;

a tonicity adjusting agent as needed to provide an osmolality of 200 to 400 mOsm; and

water;

wherein the composition is stable for at least 2 months.

2. The pharmaceutical composition according to claim 1, wherein the composition has a pH of from about 4 to about 4.5.

3. The pharmaceutical composition according to claim 1 or 2, wherein the osmolality of the composition is from about 270 to about 330 mOsm.

4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the modified cyclodextrin is selected such that the modified cyclodextrin results in the pK_a of pazopanib with said modified cyclodextrin in water being at least 0.4 lower than the pK_a of pazopanib alone in water the modified cyclodextrin results in the pK_a of pazopanib in a 10 mg pazopanib/mL water solution.

5. The pharmaceutical composition according to any one of claims 1 to 4, wherein the modified cyclodextrin is selected such that the modified cyclodextrin results in the pK_a of pazopanib with said modified cyclodextrin in water being at least 0.8 lower than the pK_a of pazopanib alone in water.

6. The pharmaceutical composition according to any one of claims 1 to 5, wherein the amount of modified cyclodextrin is from about 6.0 to about 10.0 % w/w.

7. The pharmaceutical composition according to any one of claims 1 to 6, wherein the modified cyclodextrin is selected from the group consisting of hydroxypropyl-β- cyclodextrin, methyl-β-cyclodextrin, β-cyclodextrin sulfobutylether and combinations thereof

8. The pharmaceutical composition according to any one of claims 1 to 7, wherein the modified cyclodextrin is β-cyclodextrin sulfobutylether.

9. The pharmaceutical composition according to any one of claims 1 to 8, wherein the composition is stable for at least 6 months.

10. The pharmaceutical composition according to any one of claims 1 to 9, wherein the composition is stable for at least 12 months.

11. The pharmaceutical composition according to any one of claims 1 through 10, further comprising a buffering agent.

12. The pharmaceutical composition according to claim 11, wherein said buffering agent is a phosphate buffering agent.

13. The pharmaceutical composition of any one of claims 1 through 12, wherein the pH adjusting agent is selected from the group consisting of sodium hydroxide, hydrochloric acid and combinations thereof.

14. The pharmaceutical composition of any one of claims 1 through 13, wherein the modified cyclodextrin is suitable for administration to the eye of a human.

15. The pharmaceutical composition of any one of claims 1 to 14, wherein the composition is an eye drop formulation suitable for administration to a human.

16. A pharmaceutical composition comprising:
about 10 mg pazopanib/mL of the composition;

about 2.0 to about 13.0% w/w of a modified cyclodextrin; and

a pH adjusting agent as needed to provide a pH of 3.5 to 5.7;

a tonicity adjusting agent as needed to provide an osmolality of 200 to 400 mOsm; and

water;

wherein the composition has a U_{CD} value in the range of 0.0002 to 0.6 at a temperature of 25°C, and wherein the composition is stable for at least 2 months.

17. The pharmaceutical composition according to claim 16, wherein the modified cyclodextrin is selected from the group consisting of hydroxypropyl-β- cyclodextrin, methyl-β-cyclodextrin, β-cyclodextrin sulfobutylether and combinations thereof

18. The pharmaceutical composition according to claim 16 or 17, wherein the modified cyclodextrin is β-cyclodextrin sulfobutylether.

19. The pharmaceutical composition according to any one of claims 16 to 18, wherein the amount of the modified cyclodextrin is in the range of about 6.0 % to about 10.0 % w/w.

20. The pharmaceutical composition according to any one of claims 16 to 19, wherein the osmolality of the composition is in the range of 270 to 330 mOsm.

22. The pharmaceutical composition according to any one of claims 16 to 20, further comprising a buffering agent.

23. The pharmaceutical composition according to claim 22, wherein said buffering agent is a phosphate buffering agent.

24. The pharmaceutical composition according to any one of claims 16 through 23, wherein the pH adjusting agent is selected from the group consisting of sodium hydroxide, hydrochloric acid and combinations thereof.

25. The pharmaceutical composition according to any one of claims 16 through 24, wherein the pH of said ophthalmic composition is in the range of 4.0 to 4.5.

26. The pharmaceutical composition according to any one of claims 16 through 25, wherein the composition is stable for at least 6 months.

27. The pharmaceutical composition according to any one of claims 16 through 26, wherein the composition is stable for at least 12 months.

28. The pharmaceutical composition of any one of claims 16 through 27, wherein the modified cyclodextrin is suitable for administration to the eye of a human.

29. The pharmaceutical composition of any one of claims 16 to 18, wherein the composition is an eye drop formulation suitable for administration to a human.

30. A pharmaceutical composition comprising:
about 10 mg pazopanib/mL of the composition;
about 2.0 to about 13.0% w/w of a modified cyclodextrin; and
a pH adjusting agent as needed to provide a pH of 3.5 to 5.7;
a tonicity adjusting agent as needed to provide an osmolality of 200 to 400 mOsm; and
water;
wherein the composition is a super-saturated aqueous solution of pazopanib, and wherein the composition is stable for at least 2 months.

31. The pharmaceutical composition according to claim 30, wherein the modified cyclodextrin is selected from the group consisting of hydroxypropyl-β- cyclodextrin, methyl-β-cyclodextrin, β-cyclodextrin sulfobutylether and combinations thereof.

32. The pharmaceutical composition according to claim 30 or 31, wherein the modified cyclodextrin is β-cyclodextrin sulfobutylether.

33. The pharmaceutical composition according to any one of claims 30 to 32, wherein the amount of the modified cyclodextrin is in the range of about 6.0 % to about 10.0 % w/w.

34. The pharmaceutical composition according to any one of claims 30 to 33, wherein the osmolality of the composition is in the range of 270 to 330 mOsm.

35. The pharmaceutical composition according to any one of claims 30 to 34, further comprising a buffering agent.

36. The pharmaceutical composition according to claim 35, wherein said buffering agent is a phosphate buffering agent.

37. The pharmaceutical composition according to any one of claims 30 to 36, wherein the pH adjusting agent is selected from the group consisting of sodium hydroxide, hydrochloric acid and combinations thereof.

38. The pharmaceutical composition according to any one of claims 30 to 37, wherein the pH of the ophthalmic composition is in the range of about 4.0 to about 4.5.

39. The pharmaceutical composition according to any one of claims 30 to 37, wherein the composition is stable for at least 6 months.

40. The pharmaceutical composition according to any one of claims 30 to 39, wherein the composition is stable for at least 12 months.

41. The pharmaceutical composition of any one of claims 30 to 40, wherein the modified cyclodextrin is suitable for administration to the eye of a human.

42. The pharmaceutical composition of any one of claims 30 to 41, wherein the composition is an eye drop formulation suitable for administration to a human.

43. A pharmaceutical composition comprising:
about 10 mg pazopanib/mL of the composition;
about 2.0 to about 13.0 % w/w of a modified cyclodextrin;
a pH adjusting agent as needed to provide a pH of 3.5 to 5.7;
a tonicity adjusting agent as needed to provide an osmolality of 200 to 400 mOsm; and
water.

44. The pharmaceutical composition according to claim 43, wherein the modified cyclodextrin is selected from the group consisting of hydroxypropyl-β- cyclodextrin, methyl-β-cyclodextrin, β-cyclodextrin sulfobutylether and combinations thereof.

45. The pharmaceutical composition according to claim 43 or 44, wherein the modified cyclodextrin is β-cyclodextrin sulfobutylether.

46. The pharmaceutical composition according to any one of claims 43 to 45, wherein the amount of the modified cyclodextrin is in the range of about 6.0 % to about 10.0 % w/w.

47. The pharmaceutical composition according to any one of claims 43 to 45, wherein the osmolality of the composition is in the range of 270 to 330 mOsm.

48. The pharmaceutical composition according to any one of claims 43 to 47, further comprising a buffering agent.

49. The pharmaceutical composition according to claim 48, wherein said buffering agent is a phosphate buffering agent.

50. The pharmaceutical composition according to any one of claims 43 to 49, wherein the pH adjusting agent is selected from the group consisting of sodium hydroxide, hydrochloric acid and combinations thereof.

51. The pharmaceutical composition according to any one of claims 43 to 50, wherein the pH of the ophthalmic composition is in the range of about 4.0 to about 4.5.

52. The pharmaceutical composition of any one of claims 43 to 50, wherein the modified cyclodextrin is suitable for administration to the eye of a human.\

53. The pharmaceutical composition of any one of claims 43 to 52, wherein the composition is an eye drop formulation suitable for administration to a human.

54. A pharmaceutical composition comprising:
about 10 mg pazopanib/mL of the composition;
about 9 % β-cyclodextrin sulfobutylether;
a pH adjusting agent as needed to provide a pH of 3.5 to 5.7;
a tonicity adjusting agent as needed to provide an osmolality of 200 to 400 mOsm; and
water.

55. The pharmaceutical composition of claim 54, wherein the composition is an eye drop formulation suitable for administration to a human.

56. A method of preparation of a super-saturated solution of pazopanib, said method comprising:

forming an aqueous solution of an acid addition salt of pazopanib and a modified cyclodextrin suitable for use in an ophthalmic formulation; and

adjusting the pH of said solution to between 3.5 to 5.7 to obtain a super-saturated solution of pazopanib, wherein the concentration of the acid addition salt of pazopanib solubilized in the super-saturated solution is equivalent to about 10 mg/ml of pazopanib.

57. The method according to claim 56, wherein the acid addition salt of pazopanib is pazopanib hydrochloride.

58. The method according to claim 56 or 57, wherein the modified cyclodextrin is selected from the group consisting of hydroxypropyl-β- cyclodextrin, methyl-β-cyclodextrin, β-cyclodextrin sulfobutylether and combinations thereof

59. The method according to any one of claims 56 to 58, wherein the modified cyclodextrin is β-cyclodextrin sulfobutylether.

60. The method according to any one of claims 56 to 59, wherein the amount of the modified cyclodextrin is in the range of about 2.0% to about 13.0% w/w.

61. The method according to any one of claims 56 to 60, wherein the amount of the modified cyclodextrin is in the range of about 6.0% to about 10.0% w/w.

What is claimed is:

1. A pharmaceutical composition comprising:
about 10 mg pazopanib/mL of the composition;
about 2.0 to about 13.0 % w/w of a modified cyclodextrin,;
a pH adjusting agent as needed to provide a pH of 3.5 to 5.7;
a tonicity adjusting agent as needed to provide an osmolality of 200 to 400 mOsm; and
water.

2. A pharmaceutical composition according to claim 1 comprising:
about 10 mg pazopanib/mL of the composition;
from about 2.0 to about 13.0 % w/w of a modified cyclodextrin, said modified cyclodextrin being selected such that the modified cyclodextrin results in the pK_a of pazopanib with said modified cyclodextrin in water being lower than the pK_a of pazopanib alone in water;
a pH adjusting agent as needed to provide a pH of 3.5 to 5.7;
a tonicity adjusting agent as needed to provide an osmolality of 200 to 400 mOsm; and
water;
wherein the composition is stable for at least 2 months.

3. The pharmaceutical composition according to claim 2, wherein the modified cyclodextrin is selected such that the modified cyclodextrin results in the pK_a of pazopanib with said modified cyclodextrin in water being at least 0.4 lower than the pK_a of pazopanib alone in water the modified cyclodextrin results in the pK_a of pazopanib in a 10 mg pazopanib/mL water solution.

4. The pharmaceutical composition according to any one of claims 2 or 3, wherein the modified cyclodextrin is selected such that the modified cyclodextrin results in the pK_a of pazopanib with said modified cyclodextrin in water being at least 0.8 lower than the pK_a of pazopanib alone in water.

5. A pharmaceutical composition according to claim 1 comprising:
about 10 mg pazopanib/mL of the composition;

about 2.0 to about 13.0% w/w of a modified cyclodextrin; and

a pH adjusting agent as needed to provide a pH of 3.5 to 5.7;

a tonicity adjusting agent as needed to provide an osmolality of 200 to 400 mOsm; and

water;

wherein the composition has a U_{CD} value in the range of 0.0002 to 0.6 at a temperature of 25°C, and wherein the composition is stable for at least 2 months.

6. A pharmaceutical composition according to claim 1 comprising:

about 10 mg pazopanib/mL of the composition;

about 2.0 to about 13.0% w/w of a modified cyclodextrin; and

a pH adjusting agent as needed to provide a pH of 3.5 to 5.7;

a tonicity adjusting agent as needed to provide an osmolality of 200 to 400 mOsm; and

water;

wherein the composition is a super-saturated aqueous solution of pazopanib, and wherein the composition is stable for at least 2 months.

7. The pharmaceutical composition according to any of the preceding claims, wherein the composition has a pH of from about 4 to about 4.5.

8. The pharmaceutical composition according to claim 1 to 6, wherein the osmolality of the composition is from about 270 to about 330 mOsm.

9. The pharmaceutical composition according to claims 1 to 6, wherein the modified cyclodextrin is selected from the group consisting of hydroxypropyl-β- cyclodextrin, methyl-β-cyclodextrin, β-cyclodextrin sulfobutylether and combinations thereof.

10. The pharmaceutical composition according to claim 9, wherein the modified cyclodextrin is β-cyclodextrin sulfobutylether.

11. The pharmaceutical composition according to claims 9 and 10, wherein the amount of the modified cyclodextrin is in the range of about 6.0 % to about 10.0 % w/w.

12. The pharmaceutical composition of any one of the preceding claims, wherein the modified cyclodextrin is suitable for administration to the eye of a human.

13. The pharmaceutical composition of any one of the preceding claims, wherein the composition is an eye drop formulation suitable for administration to a human.

14. The pharmaceutical composition according to any one of the preceding claims, wherein the composition is stable for at least 6 months.

15. The pharmaceutical composition according to any one of the preceding claims, wherein the composition is stable for at least 12 months.

16. The pharmaceutical composition according to any one of the preceding claims, further comprising a buffering agent.

17. The pharmaceutical composition according to any one of the preceding claims, wherein said buffering agent is a phosphate buffering agent.

18. The pharmaceutical composition according to any one of the preceding claims, wherein the pH adjusting agent is selected from the group consisting of sodium hydroxide, hydrochloric acid and combinations thereof.

19. A pharmaceutical composition according to claim 1 comprising:
about 10 mg pazopanib/mL of the composition;
about 9 % β-cyclodextrin sulfobutylether;
a pH adjusting agent as needed to provide a pH of 3.5 to 5.7;
a tonicity adjusting agent as needed to provide an osmolality of 200 to 400 mOsm; and

water.

20. The pharmaceutical composition of claim 19, wherein the composition is an eye drop formulation suitable for administration to a human.

21. A method of preparation of a super-saturated solution of pazopanib, said method comprising:

forming an aqueous solution of an acid addition salt of pazopanib and a modified cyclodextrin suitable for use in an ophthalmic formulation; and

adjusting the pH of said solution to between 3.5 to 5.7 to obtain a super-saturated solution of pazopanib, wherein the concentration of the acid addition salt of pazopanib solubilized in the super-saturated solution is equivalent to about 10 mg/ml of pazopanib.

22. The method according to claim 21, wherein the acid addition salt of pazopanib is pazopanib hydrochloride.

23. The method according to claim 21 or 22, wherein the modified cyclodextrin is selected from the group consisting of hydroxypropyl-β- cyclodextrin, methyl-β-cyclodextrin, β-cyclodextrin sulfobutylether and combinations thereof.